| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Edwards Lifesciences Corporation$83.04
+0.41 (+0.5%)
C 52Pipeline Score MedTech · Commercial
Market Cap
49.39 B
EPS
1.84
P/E Ratio
46.6 $
Value Trade
428.17 M
SEC Financials
Q1 2026Dilution Risk
Revenue
1.65 B
R&D Expenses
263.30 M
Operating CF
43.80 M
Total Assets
13.32 B
Total Liabilities
2.99 B
Equity
10.33 B
D/E Ratio
12,345
7.04 %
Week
7.04 %
1 Month
9.13 %
3 Month
1.66 %
6 Month
-7.89 %
5 Year
6,649.91 %
All Time
Cash Data
Cash Position
3.67 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 6, 2026
Overview
Volume
6.71 M
52 Week Range
72.30 - 87.89
% held by Insiders
1.29 %
% held by Institutions
90.94 %
Enterprise Value
46.42 B
Total Shares
575.63 M
Short %
1.99 %
Float Shares
571.02 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
C52
Pipeline Score $3.1B
Pipeline ValueValuation Signal
1
Drugs Scored0.2x
rNPV / MCap Top 81%
Mid Cap (rank 174 of 913)
Percentile RankEdwards Lifesciences Corporation carries a moderate pipeline score (52/100), with $3.7B risk-adjusted pipeline value, led by Ketotifen in Widespread Chronic Pain (Phase 3), across $91B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ketotifen Small molecule | Widespread Chronic Pain | Phase 3 | NCT02984397 | 54% | $3.7B | COMPLETED | 44 | - | - | Jan 1, 2020 | - | Feb 20, 2020 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in EW
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
EW Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
EWEdwards Lifesciences Reports Second Quarter Results
Edwards Lifesciences reported a strong financial performance for Q2 2026, with sales rising 13.6% to $1.74 billion. TAVR sales also showed significant growth, increasing by 11.3%. The company's adjusted EPS was reported at $0.78, reflecting robust earnings. Recent clinical data further supports their leading position in the market.
Read more →EWEdwards Lifesciences to Host Earnings Conference Call on July 23, 2026
Edwards Lifesciences plans to announce its operating results for Q2 2026 on July 23. The company will host a conference call at 5:00 p.m. ET to discuss these results. Participants can join the call via phone or access it through the company's Investor Relations website.
Read more →EWEdwards’ Structural Heart Leadership Demonstrated Through Expanding Body of Scientific Evidence at New York Valves
The article discusses Edwards Lifesciences' contributions to structural heart leadership, highlighted by their expanding body of scientific evidence presented at the New York Valves event. However, specific details about the evidence or findings are not provided in the text.
Read more →EWEdwards Lifesciences Announces Appointment of CFO
Edwards Lifesciences has announced the appointment of a new Chief Financial Officer. The announcement is part of the company's ongoing efforts to strengthen its leadership team. Further details regarding the new CFO's background and experience were not provided in the article.
Read more →EWTen-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences’ Resilia Tissue
Edwards Lifesciences has released ten-year pivotal data showcasing the long-term durability of its Resilia Tissue. This data is expected to influence future clinical applications and enhance the understanding of the product's performance over an extended period. The findings could play a significant role in the company's ongoing research and development efforts.
Read more →EWEdwards Lifesciences to Present at the BofA Securities 2026 Health Care Conference
Edwards Lifesciences announced its participation in the BofA Securities 2026 Health Care Conference, scheduled for May 12, 2026. CEO Bernard Zovighian will engage in a fireside chat at 3:40 p.m. PT, with a live webcast available for investors. The event underscores the company's commitment to patient-focused innovations.
Read more →EWEdwards Lifesciences Reports First Quarter Results
Edwards Lifesciences reported a strong financial performance for Q1 2026, with sales increasing by 16.7% to $1.65 billion. The company raised its full-year guidance for sales growth and adjusted EPS, reflecting robust demand for its TAVR and TMTT products. Despite some challenges, including a significant impairment loss, the overall outlook remains positive as the company focuses on innovative therapies.
Read more →EWDocument Edwards Lifesciences Corporation One Edwards Way Irvine, CA USA 92614 Phone 949.250.2500 www.edwards.com FOR IMMEDIATE RELEASE Media Amy Meshulam, media edwards.com Investors Gerianne Sarte, investor_relations e
Edwards Lifesciences reported a strong financial performance for Q1 2026, with sales reaching $1.65 billion, a 16.7% increase year-over-year. The company is raising its full-year sales growth guidance following significant growth in Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT). Noteworthy developments include successful commercialization of new products and adjusted earnings growth, reinforcing Edwards' competitive position in the market. CEO Bernard Zovighian highlighted the commitment to addressing complex patient needs and pursuing growth opportunities within structural heart disease.
Read more →EWEdwards Lifesciences to Host Earnings Conference Call on April 23, 2026
Edwards Lifesciences has announced an upcoming earnings conference call scheduled for April 23, 2026. The event aims to provide insights into the company's financial performance and future outlook. Further details regarding the agenda and participation will likely be shared closer to the date.
Read more →EWTwo Year Data on Edwards Lifesciences’ EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits
Edwards Lifesciences has released two-year data on its EVOQUE System, highlighting significant and sustained benefits for patients. The findings suggest that the system continues to provide positive outcomes over an extended period. This data reinforces the effectiveness of the EVOQUE System in clinical settings.
Read more →EWDocument Edwards Lifesciences Corporation One Edwards Way Irvine, CA USA 92614 Phone 949.250.2500 www.edwards.com FOR IMMEDIATE RELEASE Media Amy Meshulam, 949-250-4009, media edwards.com Investors investor_relations edw
Edwards Lifesciences reported strong financial results for Q4 and the full year of 2025, with sales increasing 13.3% to $1.57 billion. The company has bolstered its outlook for 2026, projecting sales growth of 8-10% and adjusted EPS between $2.90 and $3.05. Notable performance was seen in TAVR and TMTT segments, highlighting a commitment to innovation in heart therapies. Edwards aims to leverage its extensive research and prior trial successes to support continued growth in upcoming years.
Read more →EWEdwards Lifesciences to Host Earnings Conference Call on February 10, 2026
Edwards Lifesciences plans to announce its operating results for Q4 2025 on February 10, 2026. The announcement will be followed by a conference call at 5:00 p.m. ET to discuss the results. Participants can join the call via specified phone numbers or through the company's Investor Relations website.
Read more →EWEdwards Lifesciences to Present at the TD Cowen 46th Annual Health Care Conference
Edwards Lifesciences Corporation will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026. CFO Scott Ullem is scheduled to present at 9:50 a.m. ET. A live webcast of the presentation will be available on the company's investor relations website, with an archived version accessible later.
Read more →EWFDA Approves Edwards Lifesciences’ SAPIEN M3 Mitral Valve Replacement System as First Transseptal Transcatheter Therapy
Edwards Lifesciences has received FDA approval for its SAPIEN M3 mitral valve replacement system, marking it as the first transseptal transcatheter therapy for mitral regurgitation. This system is designed for patients who are not candidates for surgery or other treatments. The approval is supported by successful trial data demonstrating significant improvements in patient outcomes.
Read more →EWEdwards Lifesciences Reaffirms Strategy for Sustainable, Differentiated Growth at Annual Investor Conference
Edwards Lifesciences reaffirmed its strategy for sustainable growth at its annual investor conference, highlighting its commitment to innovative therapies for structural heart diseases. The company aims to address unmet needs in aortic stenosis, mitral regurgitation, and other conditions. CEO Bernard Zovighian emphasized the importance of delivering differentiated innovations to improve patient care and outcomes. Edwards is focused on expanding its portfolio and enhancing patient access to its therapies.
Read more →EWEdwards Lifesciences Corporation One Edwards Way Irvine, CA USA 92614 Phone: 949.250.2500 www.edwards.com FOR IMMEDIATE RELEASE Media Contact: Amy Meshulam, 949-250-4009 Investor Contact: Mark Wilterding, 949-250-6826
Edwards Lifesciences has announced a planned transition of its Chief Financial Officer, Scott Ullem, who will depart by mid-2026. The company is starting the selection process for a new CFO and aims to ensure a smooth transfer of responsibilities during this transition. Following the appointment of a successor, Ullem will remain with the company in an advisory position.
Read more →EWDocument Edwards Lifesciences Corporation One Edwards Way Irvine, CA USA 92614 Phone 949.250.2500 www.edwards.com FOR IMMEDIATE RELEASE Media Contact Amy Meshulam, 949-250-4009 Investor Contact Mark Wilterding, 949-250-6
Edwards Lifesciences reported a strong financial performance for Q3 2025, with total sales reaching $1.55 billion, a 14.7% increase. The Transcatheter Aortic Valve Replacement (TAVR) segment continued to drive growth, achieving significant sales increases. New treatment guidelines and promising clinical outcomes for products like SAPIEN M3 and EVOQUE further bolster the company's outlook, leading to revised sales and earnings projections for the year. However, there was a decline in adjusted gross profit margins compared to the previous year.
Read more →EWEDWARDS (EW) ALERT: Bragar Eagel & Squire, P.C. is Investigating Edwards Lifesciences Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Edwards Lifesciences Corporation on behalf of long-term stockholders following a class action complaint filed against the company. The lawsuit alleges breaches of fiduciary duties by the board, particularly related to misleading statements concerning the expected performance of the TAVR platform. Edwards’ recent financial results for the second quarter of fiscal 2024 fell significantly below expectations, causing its stock price to plummet by 31.34%. The investigation comes in the wake of declining confidence in the TAVR business amidst rising competition and operational challenges.
Read more →EWEdwards Lifesciences Corporation Investors: Company Investigated by the Portnoy Law Firm
The Portnoy Law Firm has initiated an investigation into Edwards Lifesciences Corporation regarding possible securities fraud, encouraging investors to reach out for legal recourse. This follows a troubling financial performance report for Q2 2024, where the company reduced its revenue guidance for the Transcatheter Aortic Valve Replacement (TAVR) platform. The firm noted that the growth of structural heart therapies has strained hospital resources, potentially impacting TAVR utilization. After these disclosures, Edwards' stock price experienced a drastic decline of approximately 31.34% in one day.
Read more →EWDocument Edwards Lifesciences Corporation One Edwards Way Irvine, CA USA 92614 Phone 949.250.2500 www.edwards.com FOR IMMEDIATE RELEASE Media Contact Amy Hytowitz, 949-250-4009 Investor Contact Mark Wilterding, 949-250-6
Edwards Lifesciences reported a strong fourth quarter for 2024, with sales rising 9% to $1.39 billion. The company experienced remarkable growth in its Transcatheter Mitral and Tricuspid Therapies (TMTT), recording an 88% increase in sales. Looking ahead, Edwards is optimistic for 2025, projecting 8% to 10% sales growth and highlighting advancements in regulation and product offerings. Despite a decrease in gross profit margin, the company remains confident in its strategies and market position.
Read more →EWEDWARDS ALERT: Bragar Eagel & Squire, P.C. is Investigating Edwards Lifesciences Corp on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against Edwards Lifesciences Corp following a class action complaint regarding the company's revenue guidance for its TAVR platform. The investigation stems from a significant drop in stock price after Edwards announced disappointing financial results and revised its TAVR revenue expectations downward. This downturn raised concerns about whether the board of directors breached their fiduciary duties. The investigation aims to determine the impact of these decisions on long-term stockholders.
Read more →EWEdwards Lifesciences (EW) Faces Investor Class Action Lawsuit Over TAVM Platform Disclosures, Deadline Pending – Hagens Berman
Edwards Lifesciences Corporation is facing a class action lawsuit from investors alleging securities fraud over misleading information regarding its Transcatheter Aortic Valve Replacement (TAVR) platform. The lawsuit claims that executives provided overly optimistic forecasts for TAVR growth, which failed to materialize, as evidenced by recent financial reports showing a slowdown in sales. Following this news, the company's stock underwent a substantial decline, leading to significant losses for shareholders. The class action seeks to recover damages for affected investors.
Read more →EWEDWARDS ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Edwards Lifesciences Corp and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Edwards Lifesciences Corp, concerning securities purchased between February and July 2024. This follows Edwards' disappointing second quarter financial results and a cut to its revenue guidance for the TAVR platform. The lawsuit highlights allegations of misrepresentation regarding expected revenue and demand for the TAVR product. Following the news, Edwards' stock price plummeted by approximately 31.34% in one day, reflecting investor concerns about the company's outlook.
Read more →EWEDWARDS LIFESCIENCES CORPORATION (NYSE: EW) INVESTOR ALERT: Bernstein Liebhard LLP Reminds Edwards Lifesciences Corporation Investors of Upcoming Deadline
Bernstein Liebhard LLP has issued a reminder to investors of Edwards Lifesciences Corporation regarding an impending deadline related to a securities fraud class action lawsuit. This lawsuit, filed in the United States District Court for the Central District of California, concerns allegations of misrepresentation by the company and its senior officers. Investors who acquired shares between February 6, 2024 and July 24, 2024 are particularly urged to assess their legal rights and options.
Read more →EWEdwards Lifesciences Corporation Investors Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Edwards Lifesciences Corporation Shareholders of Deadline in Securities Fraud Class Action Lawsuit
A securities class action lawsuit has been filed against Edwards Lifesciences Corporation, alleging that the company misrepresented the performance and growth potential of its Transcatheter Aortic Valve Replacement (TAVR) product. The lawsuit cites misleading statements and concealment of material facts about the TAVR platform during the specified class period. Investors are advised to consider their options, including becoming lead plaintiffs, before the upcoming deadline of December 13, 2024.
Read more →EW▲ +5.7%on this newsshared move
Edwards Lifesciences Corporation Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before December 13, 2024 to Discuss Your Rights – EW
Edwards Lifesciences Corporation is facing a class-action lawsuit related to allegations of securities fraud, with a focus on misleading information about its expected revenue for 2024. The complaint outlines claims regarding the company’s Transcatheter Aortic Valve Replacement (TAVR) platform, which suffered a significant revenue guidance reduction following disappointing quarterly results. The lawsuit suggests that Edwards was aware of challenges to the TAVR platform's growth but continued to promote it amidst increasing competition from new therapies. Affected shareholders are encouraged to register for the class action before the December 13, 2024 deadline.
Read more →EWEdwards Lifesciences Corporation Investors: Please contact the Portnoy Law Firm to recover your losses. December 13, 2024 Deadline to file Lead Plaintiff Motion.
Edwards Lifesciences Corporation is facing a class action lawsuit due to alleged misleading statements made during the period from February 6, 2024, to July 24, 2024. The lawsuit claims that the company downplayed risks affecting its revenue outlook and overestimated the growth potential of its Transcatheter Aortic Valve Replacement (TAVR) technology. Following the release of below-expectation TAVR results in July 2024, the company's stock price fell by more than 31%. Investors are encouraged to learn about their rights and the possibility of recovering losses before the December 13, 2024, filing deadline.
Read more →EWEdwards Lifesciences Corporation (EW) Investors: December 13, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
A securities class action lawsuit has been filed against Edwards Lifesciences Corporation, alleging that the company provided misleading statements related to the growth of its Transcatheter Aortic Valve Replacement (TAVR) product. The lawsuit claims that the company concealed adverse facts regarding the actual state of its TAVR platform, which could affect investor confidence. The lead plaintiff deadline for investors is set for December 13, 2024, as Kessler Topaz Meltzer & Check, LLP encourages those who suffered losses to participate.
Read more →EWEdwards Lifesciences (EW) Faces Investor Class Action Over Loss of $16 Billion Of Market Capitalization – Hagens Berman
Edwards Lifesciences Corporation is facing a class action lawsuit initiated by Hagens Berman, alleging that the company made misleading statements regarding its Transcatheter Aortic Valve Replacement (TAVR) platform's growth prospects. The lawsuit follows a significant decline in TAVR growth guidance and poor financial results announced on July 24, 2024, which led to a 31% drop in share price, erasing $16 billion in market value. Investigators are examining whether the company provided inaccurate information to investors amid rising competition in the market.
Read more →EWEdwards Lifesciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before December 13, 2024 to Discuss Your Rights – EW
Edwards Lifesciences Corporation is facing a class action lawsuit due to alleged securities law violations stemming from misleading statements regarding the company's financial performance and growth expectations for its Transcatheter Aortic Valve Replacement (TAVR) platform. After the company reported disappointing second-quarter results for fiscal year 2024, including a severe reduction in revenue guidance for TAVR, its stock price plummeted by approximately 31% in a single day. Shareholders who purchased shares between February 6 and July 24, 2024, are encouraged to register for participation in the class action ahead of the December 13, 2024, deadline.
Read more →EWEDWARDS LIFESCIENCES has been Sued for Securities Fraud after Stock Plummets 31%; Contact the Firm before December 13 Class Action Deadline (NYSE:EW)
Edwards Lifesciences Corporation is facing a securities fraud lawsuit following a 31% decline in its stock price. The lawsuit alleges that the company made materially false and misleading statements regarding the demand for its Transcatheter Aortic Valve Replacement (TAVR) therapies. A significant reduction in financial guidance and disappointing results reported on July 24, 2024, led to the sharp decline in stock prices. Investors are encouraged to join the case before the December 13, 2024 deadline.
Read more →EWEdwards Lifesciences Corporation Class Action: The Gross Law Firm Reminds Edwards Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 13, 2024 – EW
The Gross Law Firm has informed shareholders of Edwards Lifesciences Corporation (NYSE: EW) about a pending class-action lawsuit related to alleged misleading statements about the company's revenues and TAVR product growth forecasts. The lawsuit stems from financial results announced on July 24, 2024, which fell short of expectations, leading to a significant drop in Edwards' stock price. Shareholders who purchased shares during the specified class period are encouraged to register for participation in the lawsuit, with a lead plaintiff deadline set for December 13, 2024.
Read more →EWEdwards Lifesciences Corporation Class Action Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the EW Class Action
Robbins LLP has announced a class action on behalf of investors who purchased Edwards Lifesciences Corporation (EW) securities between February 6, 2024, and July 24, 2024. The firm alleges that Edwards misled investors regarding the growth potential of its core product, the Transcatheter Aortic Valve Replacement (TAVR). This came to light after Edwards reported disappointing financial results and lowered its revenue guidance for the TAVR platform. Investors saw a dramatic decline in stock price by around 31.34% following this revelation.
Read more →EWEDWARDS LIFESCIENCES CORPORATION (NYSE: EW) INVESTOR ALERT: Investors With Large Losses in Edwards Lifesciences Corporation Should Contact Bernstein Liebhard LLP To Discuss Their Rights
A securities class action lawsuit has been filed against Edwards Lifesciences Corporation on behalf of investors who acquired its securities between February 6, 2024, and July 24, 2024. The lawsuit alleges that the company made false representations concerning its Transcatheter Aortic Valve Replacement platform and demand in lower-penetrated markets. Investors are encouraged to contact Bernstein Liebhard LLP to discuss their rights and the possibility of serving as lead plaintiffs. The law firm operates on a contingency fee basis, meaning shareholders incur no upfront costs.
Read more →EWEDWARDS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Edwards Lifesciences Corp and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Edwards Lifesciences Corp for potential misrepresentation of revenue expectations related to its TAVR platform. The lawsuit encompasses all individuals who acquired Edwards securities between February 6 and July 24, 2024. Following disappointing financial results highlighted on July 24, Edwards reduced its revenue guidance for the TAVR product, attributing the shortfall to pressure from expanded structural heart therapies. The company also reported a substantial drop in stock price, declining over 31% in one day.
Read more →EWEdwards Lifesciences Corporation One Edwards Way Irvine, CA USA 92614 Phone: 949.250.2500 www.edwards.com FOR IMMEDIATE RELEASE Media Contact: Amy Hytowitz, 949-250-4009 Investor Contact: Mark Wilterding, 949-250-6826 ED
Edwards Lifesciences has announced its decision to sell its Critical Care product group to BD for $4.2 billion in an all-cash transaction, marking a shift in the company's focus towards structural heart disease innovation. The decision comes as Edwards aims to utilize the proceeds to support strategic investments in technologies for various cardiac conditions. The sale will enhance financial flexibility, and the leadership emphasizes its commitment to addressing substantial unmet patient needs. The transaction is subject to regulatory approvals and is expected to close by the end of 2024.
Read more →EW▼ -8.1%on this news
CLASP IID ONE-YEAR DATA CONFIRM SAFETY AND EFFICACY OF EDWARDS PASCAL SYSTEM FOR DEGENERATIVE MITRAL REGURGITATION Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares...
Edwards Lifesciences announced positive one-year results from the CLASP IID trial, demonstrating the safety and efficacy of the PASCAL system for treating degenerative mitral regurgitation. The trial showed significant improvements in patient outcomes, including high rates of MR reduction and low adverse event rates. The findings were presented at the TCT symposium and published in JACC: Cardiovascular Interventions.
Read more →EW▼ -8.1%on this news
TRISCEND II SIX-MONTH DATA FOR FIRST 150 PATIENTS SUCCESSFULLY DEMONSTRATE SAFETY AND EFFICACY OF EDWARDS EVOQUE SYSTEM FOR SEVERE TRICUSPID REGURGITATION Edwards Lifesciences Corporation (NYSE: EW) today announced successful results from TRISCEND II, a randomized controlled pivotal trial designed to...
Edwards Lifesciences announced positive results from the TRISCEND II trial, evaluating the EVOQUE tricuspid valve replacement system. The trial met primary safety and effectiveness endpoints for the first 150 patients, showing significant improvements in tricuspid regurgitation and quality of life. An FDA Advisory Committee meeting is anticipated in January 2024, with potential US approval in mid-2024.
Read more →EWEDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Sept. 30, 2023. Recent Highlights and Outlook Q3 sales grew 12 ...
Edwards Lifesciences reported strong Q3 results with a 12% sales increase to $1.48 billion and notable growth in TAVR sales. The company received several key regulatory approvals, including for the EVOQUE tricuspid replacement system. Despite a decrease in gross profit margin, the outlook for 2023 remains positive with expected sales growth of 10 to 13%.
Read more →EWFIVE-YEAR DATA FROM PARTNER 3 TRIAL DEMONSTRATE EXCELLENT SURVIVAL FOR PATIENTS RECEIVING EDWARDS SAPIEN 3 VALVE Edwards Lifesciences (NYSE: EW) today announced new data from the PARTNER 3 trial demonstrating continued low rates of all-cause mortality, disabling ...
Edwards Lifesciences announced five-year data from the PARTNER 3 trial, showing low rates of all-cause mortality, disabling stroke, and rehospitalization in TAVR patients. The findings indicate that the SAPIEN 3 valve offers significant clinical benefits and durability compared to surgical options. These results were presented at the TCT conference and published in a leading medical journal.
Read more →EWEDWARDS EVOQUE TRANSCATHETER TRICUSPID VALVE REPLACEMENT SYSTEM RECEIVES CE MARK Edwards Lifesciences Corporation (NYSE: EW) today announced the company's EVOQUE tricuspid valve replacement system received CE Mark for the...
Edwards Lifesciences has received CE Mark approval for its EVOQUE tricuspid valve replacement system, marking it as the first transcatheter therapy for tricuspid regurgitation. The system aims to improve treatment options for patients suffering from this condition in Europe. Clinical studies have shown promising results, including high survival rates and significant quality-of-life enhancements.
Read more →EWEDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON OCTOBER 25, 2023 Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2023 after the market closes on...
Edwards Lifesciences plans to announce its operating results for Q3 2023 on October 25, 2023. The announcement will be followed by a conference call at 5:00 p.m. ET to discuss the results. Participants can join the call via specific phone numbers or access it online through the company's Investor Relations section.
Read more →EWEDWARDS LIFESCIENCES TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE Edwards Lifesciences Corporation (NYSE: EW) today announced it is scheduled to present at the 2023 Wells Fargo Healthcare Conference on Thursday,...
Edwards Lifesciences Corporation announced its participation in the 2023 Wells Fargo Healthcare Conference, scheduled for September 7, 2023. CEO Bernard Zovighian and CFO Scott B. Ullem will present at 11:00 a.m. ET. A live webcast will be available for interested parties, with an archived version accessible later.
Read more →EWEDWARDS LIFESCIENCES REPORTS SECOND QUARTER RESULTS Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2023. Highlights and Outlook Q2 sales grew 11 percent ...
Edwards Lifesciences reported a strong second quarter for 2023, with sales growing 11% to $1.53 billion. The company achieved double-digit growth across all product groups and raised its full-year sales guidance. However, it noted a decrease in gross profit margin and slower growth in Japan. The CEO expressed confidence in the company's innovative therapies and long-term outlook.
Read more →EWDocument Edwards Lifesciences Corporation One Edwards Way Irvine, CA USA 92614 Phone 949.250.2500 www.edwards.com FOR IMMEDIATE RELEASE Media Contact Sarah Huoh, 949-250-5070 Investor Contact Mark Wilterding, 949-250-682
Edwards Lifesciences reported strong second quarter results with sales reaching $1.53 billion, an 11% increase year-over-year. TAVR sales grew 9%, benefiting from improved hospital staffing in the U.S. Despite challenges such as lower-than-expected growth in Japan and increased operational expenses, the company raised its full-year sales outlook to $5.9 to $6.1 billion. The CEO expressed confidence in the company’s growth strategy and ongoing innovations aimed at improving patient care.
Read more →EWEDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JULY 26, 2023 Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2023 after the market closes on Wednesday,...
Edwards Lifesciences will announce its operating results for Q2 2023 on July 26, 2023, after market close. A conference call is scheduled for 5:00 p.m. ET the same day to discuss these results. Participants can join via phone or access the call online through the company's Investor Relations section.
Read more →EWEdwards Lifesciences Corporation One Edwards Way Irvine, CA USA 92614 Phone: 949.250.2500 Fax: 949.250.2525 www.edwards.com FOR IMMEDIATE RELEASE Media Contact: Sarah Huoh, 949-250-5070 Investor Contact: Mark Wilterding,
FOR IMMEDIATE RELEASE Media Contact: Sarah Huoh, 949-250-5070 Investor Contact: Mark Wilterding, 949-250-6826 EDWARDS LIFESCIENCES ANNOUNCES CEO SUCCESSION PLAN At the 2023 annual meeting, Mussallem will stand for election as non-executive chairman of Edwards Board. He will b
Read more →EWEdwards Lifesciences Corporation One Edwards Way Irvine, CA USA 92614 Phone: 949.250.2500 www.edwards.com FOR IMMEDIATE RELEASE Media Contact: Sarah Huoh, 949-250-5070 Investor Contact: Mark Wilterding, 949-250-6826 EDWA
FOR IMMEDIATE RELEASE Media Contact: Sarah Huoh, 949-250-5070 Investor Contact: Mark Wilterding, 949-250-6826 EDWARDS LIFESCIENCES ANNOUNCES $750 MILLION ACCELERATED SHARE REPURCHASE IRVINE, Calif., Nov. 1, 2022 Edwards Lifesciences (NYSE: EW) today announced that it has exec
Read more →EWDocument Edwards Lifesciences Corporation One Edwards Way Irvine, CA USA 92614 Phone 949.250.2500 Fax 949.250.2525 www.edwards.com FOR IMMEDIATE RELEASE Media Contact Sarah Huoh, 949-250-5070 Investor Contact Mark Wilter
Media Contact Sarah Huoh, 949-250-5070 Investor Contact Mark Wilterding, 949-250-6826 EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS IRVINE, Calif., October 27, 2021 - Edwards Lifesciences (NYSE EW) today reported financial results for the quarter ended September 30, 2021.
Read more →EWThird Quarter Highlights and Outlook
Media Contact: Sarah Huoh, 949-250-5070 Investor Contact: Mark Wilterding, 949-250-6826 EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS IRVINE, Calif., October 21, 2020 - Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 20
Read more →EWSecond Quarter Highlights and Outlook
Media Contact: Sarah Huoh, 949-250-5070 Investor Contact: Mark Wilterding, 949-250-6826 EDWARDS LIFESCIENCES REPORTS SECOND QUARTER RESULTS IRVINE, Calif., July 23, 2020 - Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structu
Read more →EWEdwards’ HemoSphere Platform Receives Expanded Use Indication From Health Canada in Treatment of COVID-19 Patients
IRVINE, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that Health Canada approved an expanded indication for use o
Read more →EWForward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking
Media Contact: Sarah Huoh, 949-250-5070 Investor Contact: Mark Wilterding, 949-250-6826 EDWARDS LIFESCIENCES REPORTS FIRST QUARTER RESULTS IRVINE, Calif., April 23, 2020 - Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structu
Read more →EWThird Quarter and Recent Highlights
Media Contact: Sarah Huoh, 949-250-5070 Investor Contact: Mark Wilterding, 949-250-2826 EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS IRVINE, Calif., October 23, 2019 - Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for struc
Read more →EWSecond Quarter and Recent Highlights
Media Contact: Sarah Huoh, 949-250-5070 Investor Contact: Mark Wilterding, 949-250-2826 EDWARDS LIFESCIENCES REPORTS SECOND QUARTER RESULTS IRVINE, Calif., July 23, 2019 - Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structu
Read more →EWFirst Quarter and Recent Highlights
Media Contact: Sarah Huoh, 949-250-5070 Investor Contact: Investor Relations, 949-250-2806 EDWARDS LIFESCIENCES REPORTS FIRST QUARTER RESULTS IRVINE, Calif., April 23, 2019 - Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for stru
Read more →EWEdwards Lifesciences Choses Selectica SmartContracts(R) Solution
SAN MATEO, CA--(Marketwired - Jun 29, 2015) - Selectica, Inc. (NASDAQ: SLTC), a leading provider of contract management, supply management -- from source to pay, and configuration solutions, announced that Edwards Lifesciences chose to implement Selectica SmartContracts to manage
Read more →EWEdwards LifeSciences Lead Rise in European Tissue Heart Valve Market
VANCOUVER, BC, Jan. 27, 2015 (GLOBE NEWSWIRE) -- via PRWEB - According to a new report published by iData Research, despite advancements in design, the mechanical heart valve market continues to decline due to the general consensus among healthcare facilities and employees in Eur
Read more →EWEdwards Lifesciences, Boston Scientific and Medtronic Fuel Double Digit Growth in the European Transcatheter Heart Valve Devices Market
VANCOUVER, BC, May 12, 2014 (GLOBE NEWSWIRE) -- via PRWEB - According to a new report on the European Market for Cardiac Surgery Devices by iData Research (http://www.idataresearch.com), the leading global authority in medical device and pharmaceutical market research, the total
Read more →EWEdwards Lifesciences Corp. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Edwards Lifesciences Corp. and Its Board of Directors and a Lead Plaintiff Deadline of November 18, 2013 -- EW
NEW YORK, Oct. 29, 2013 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased Edwards Lifesciences Corporation ("Edwards Lifesci
Read more →EWEdwards Lifesciences Corporation SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Class Action Against Edwards Lifesciences Corporation and Its Board of Directors and a Lead Plaintiff Deadline of November 18, 2013 -- EW
NEW YORK, NY--(Marketwired - Oct 15, 2013) - Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased Edwards Lifesciences Corporation ("Edwards Lifesc
Read more →EWEDWARDS LIFESCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Edwards Lifesciences Corp. - EW
NEW ORLEANS, LA--(Marketwired - Sep 19, 2013) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 18, 2013 to file lead plaintiff applications in a securities class action
Read more →Competitive Position
How EW ranks across every disease it competes inCompetitive Position is a premium feature
See how EW ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial